Drug Profile
Anti-Staphylococcal enterotoxin B monoclonal antibody - Mapp Biopharmaceutical
Alternative Names: hu19F1 - Mapp BiopharmaceuticalLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Mapp Biopharmaceutical
- Developer Mapp Biopharmaceutical; Tulane National Primate Research Center
- Class Antitoxins; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Staphylococcal infections
Most Recent Events
- 23 Jan 2023 Anti-Staphylococcal enterotoxin B monoclonal antibody is still in early research in USA Mapp Biopharmaceutical pipeline, January 2023)
- 28 Jun 2022 No recent reports of development identified for research development in Staphylococcal-infections in USA (Parenteral)
- 29 Jun 2020 Anti-Staphylococcal enterotoxin B monoclonal antibodies programme is still in early research in USA (Mapp Biopharmaceutical pipeline, June 2020)